A5024226964- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Cardiac Arrhythmias and Treatments
- Cardiac tumors and thrombi
- Central Venous Catheters and Hemodialysis
- Cardiac Imaging and Diagnostics
- Acute Ischemic Stroke Management
- Cardiac pacing and defibrillation studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Valve Diseases and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Cancer Treatment and Pharmacology
- Pulmonary Hypertension Research and Treatments
- Acute Myocardial Infarction Research
- Diagnosis and Treatment of Venous Diseases
- Receptor Mechanisms and Signaling
- Neurotransmitter Receptor Influence on Behavior
- Cardiovascular Effects of Exercise
- Chemotherapy-induced cardiotoxicity and mitigation
- Blood Pressure and Hypertension Studies
- Aortic Disease and Treatment Approaches
- Erythropoietin and Anemia Treatment
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Inflammatory Biomarkers in Disease Prognosis
- Cardiovascular and Diving-Related Complications
Kurashiki Central Hospital
2019-2025
Hyogo Medical University
2011
Colorado Association of School Executives
2010
BACKGROUND: The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis in patients with cancer is clinically relevant, but the evidence lacking. prolonged could have a potential benefit prevention thrombotic events; however, it also increase risk bleeding. METHODS: In multicenter, open-label, adjudicator-blinded, randomized clinical trial at 60 institutions Japan, we randomly assigned thrombosis, 1-to-1 ratio, to receive either 12-month or 3-month edoxaban...
There has been limited data on anticoagulation strategies and long-term recurrence in patients with venous thromboembolism (VTE) the era of direct oral anticoagulant (DOAC).The COMMAND VTE Registry-2 is a multicenter retrospective cohort study enrolling 5197 consecutive acute symptomatic between January 2015 August 2020 among 31 centers Japan. In this primary report, entire was divided into 5 groups; major transient risk factors (N = 475, 9.1%), minor 788, 15%), unprovoked 1913, 37%),...
Limited data are available regarding clinical outcomes after percutaneous left atrial appendage closure using WATCHMAN FLX (WM-FLX) and WATCHMAN-2.5 (WM2.5) devices in Asian patients.
Background Real-world data on clinical characteristics and outcomes related to the use of different direct oral anticoagulants (DOACs) for cancer-associated venous thromboembolism (VTE) is lacking. Methods The COMMAND VTE Registry-2 a multicenter registry enrolling 5,197 consecutive patients with acute symptomatic from 31 centers in Japan January 2015 August 2020. Our study population comprised 1,197 active cancer who were divided into edoxaban (N = 643, 54%), rivaroxaban 297, 25%), apixaban...
Patients with nonvalvular atrial fibrillation (AF) not suitable for long-term anticoagulant therapy undergo percutaneous left appendage closure (LAAC) using the WATCHMAN device. The safety and efficacy of WATCHMAN-FLX (WM-FLX) compared WATCHMAN-2.5 (WM-2.5), particularly in Asian populations, is unknown.
Percutaneous left atrial appendage closure (LAAC) reduces the incidence of stroke/bleeding events in patients with non-valvular fibrillation, high risk stroke, and contraindication continuing anticoagulation therapy. Of them, heart failure may remain at these after LAAC.
Background: Patients with appropriately selected low-risk pulmonary embolism (PE) can be treated at home, although it has been controversial whether applies to patients cancer, who are considered not low risk.
We have seen ischemic stroke associated with a high-grade device-related pedunculated thrombosis after left atrial appendage closure (LAAC) discontinuation of oral anticoagulations (OACs). Continuation OACs, including half-dose direct LAAC, may be better option for patients at high risk thromboembolism to prevent further thromboembolic events.
Abstract Background Patients with atrial fibrillation (AF) who are not suitable for long‐term anticoagulant therapy undergo percutaneous left appendage closure (LAAC). The safety and feasibility of catheter ablation (CA) procedures after LAAC remain unclear. This study aimed to clarify the CA LAAC, including in early phase within 180 days. Methods Characteristics clinical outcomes 46 patients AF had undergone both 2 years (mean age, 72 years; 29 men) were compared between those CA‐first (31...
Background Chronic thromboembolic pulmonary hypertension (CTEPH) is a life‐threatening complication post‐acute embolism (PE). The assessment of CTEPH incidence and risk factors PE in the era direct oral anticoagulants remains insufficient. Methods Results COMMAND VTE Registry‐2 (contemporary management outcomes patients with venous thromboembolism registry‐2) multicenter registry that recruited consecutive acute symptomatic from 31 centers across Japan. primary outcome was to demonstrate...
Although the late cardiac tamponade in leadless pacemaker implantation (LPI) is rare, we encountered such an incident patient with AVEIR-VR™ system on hemodialysis and warfarinization. When LPI active fixation system, should aim for successful single-attempt deployment using electrical premapping to prevent including phase.
The ONCO DVT study revealed the superiority of 12-month relative to 3-month edoxaban treatment for cancer-associated isolated distal deep vein thrombosis (DVT) regarding thrombotic risk. In this pre-specified subgroup analysis study, we stratified patients into those with a standard dose (60 mg/day; N = 151) and reduced (30 450) evaluated clinical outcomes 12- treatments. cumulative incidence symptomatic recurrent venous thromboembolism was lower in than group both 60 mg (1.3% vs. 11.6%, P...
Atrial fibrillation ablation, including pulmonary vein isolation immediately after left atrial appendage closure (LAAC), is a rare and challenging issue. Intracardiac echocardiography guidance can help identify the LAAC device position for safe ablation without device-related adverse events even implantation.